MTOR and B-cell non-Hodgkin lymphoma: Furthermore, inhibitors of mTOR were less successful in clinical studies in the treatment of B cell lymphomas than expected based on pre-clinical experiments [21], suggesting the need for multi-target approaches that include inhibitors of mTOR in conjunction with HIF-1α.